Why Are Investors Ignoring Vertex’s Good News?
Vertex Pharmaceuticals’ (NASDAQ:VRTX) woes began about a year ago when it announced the failure of an alpha-1 antitrypsin deficiency (AATD) candidate in clinical trials. A second candidate for the liver and lung disorder failed several months later. Since…
